On November 9, 2026, Frontage Holdings Corporation (Frontage) announced that it has entered into an agreement for (i) a privatization by way of scheme of arrangement through SanRex Limited, the offeror held by an investor consortium, and (ii) a subsequent asset restructuring (together, “the transaction”). Wilson Sonsini Goodrich & Rosati advised Frontage on the transaction.
Upon completion of the privatization, Frontage will become a wholly owned subsidiary of SanRex Limited. As part of the asset restructuring, Frontage’s business is expected to be divided among members of an investor consortium comprising Charles River Laboratories International, Inc. (expected to own and operate Frontage’s Exton, Pennsylvania-based bioanalysis and drug metabolism and pharmacokinetics (DMPK) business); a wholly owned subsidiary of Hangzhou Tigermed Consulting Co., Ltd., Frontage's controlling shareholder (expected to own and operate Frontage’s PRC-based business and the business currently owned and operated by Acme Bioscience, Inc. and/or its subsidiaries); and Dr. Song Li, chairman of Frontage's board of directors (expected to own and operate Frontage’s remaining business outside of the PRC). The transaction remains subject to shareholder and regulatory approvals.
Frontage is engaged in the provision of research, analytical, and development services throughout the product discovery and development continuum. Frontage provides integrated, scientifically driven support that enables biopharmaceutical and life science companies to achieve their product development goals.
The Wilson Sonsini team that advised Frontage on the transaction includes Yang Chu, Jie Zhu, Nicole Yuen, Yang Liao, Shuhan Zhang, Yuan Dong, and Yingqi Gu.
For more information, please refer to Frontage’s press release and the HKEX announcement.